Cambridge Innovation Capital (CIC) is a leading venture capital firm founded in 2012, based in Cambridge, UK, with a proprietary relationship with the University of Cambridge that provides privileged access to life sciences and deep technology opportunities. The firm manages £600 million in assets under management and has invested £350 million across more than 45 companies, leveraging its position within one of Europe's most powerful science and technology ecosystems. CIC focuses primarily on Series A investments in knowledge-intensive businesses, particularly in life sciences and deep tech sectors including quantum computing, semiconductors, microbiome therapeutics, and photonics. The firm maintains a hands-on approach with portfolio companies, offering not only capital but also expert guidance through its team of partners, operating partners, and entrepreneurs-in-residence. CIC has co-invested over £3.2 billion alongside other investors and supported more than 125 founders. The firm emphasises responsible investment and ESG principles, maintaining carbon-neutral operations and publishing annual responsible investment reports. Portfolio companies include Cambridge GaN Devices, Pragmatic Semiconductor, Riverlane, Salience Labs, Microbiotica, and CMR Surgical, which recently received a $400 million investment from Stryker.

Profile auto-generated from public sources — details unverified.